Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Date publication

mai 2026

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Wils P, Jairath V, Sands BE, Dignass A, Magro F, Rubin DT, Dotan I, Reinisch W, Dulai P, Gearry R, Ma C, Long M, Armuzzi A, Kobayashi T, Turner D, Vieujean S, Verstockt B, Hart A, Danese S, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42159038

Résumé

Prolonged washout periods between advanced therapies and investigational drugs are commonly required in inflammatory bowel disease (IBD) randomized controlled trials (RCTs). These requirements restrict patient enrollment and diverge from real-world clinical practice. This study aimed to establish an international expert consensus on washout durations for advanced therapies and conventional immunosuppressants (IS) in IBD clinical trials and to propose methodological recommendations for future study designs.

Mots clés

biologics, inflammatory bowel diseases, randomized trials, washout period

Référence

J Crohns Colitis. 2026 05 8;20(5):